Morphologic and molecular prognostic markers in prostate cancer

被引：29
|
作者：
Ross, JS [1 ]
Sheehan, CE
Dolen, EM
Kallakury, BVS
机构：
[1] Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA
[2] Albany Med Coll, Dept Radiol, Albany, NY 12208 USA
[3] Millennium Pharmaceut Inc, Cambridge, MA USA
[4] Georgetown Univ, Sch Med, Dept Pathol, Georgetown, MD USA
来源：
ADVANCES IN ANATOMIC PATHOLOGY | 2002年 / 9卷 / 02期
关键词：
prostate cancer; biomarker; prognosis; grade; stage; DNA ploidy; cell proliferation; oncogene; cell adhesion; HER-2/neu; apoptosis; proteasome;
D O I：
10.1097/00125480-200203000-00003
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
In this review, a series of traditional morphology-based measurements, relatively well-documented ancillary biomarkers, and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and are classified as category I by the College of American Pathologists' Solid Tumor Prognostic Factor Consensus Conference are compared with newer tests that are beginning to be used in clinical practice (category II) and emerging molecular-based assays that have yet to be widely validated in the published literature or in clinical trials (category III).
引用
收藏
页码：115 / 128
页数：14
相关论文
共 50 条
  • [11] Molecular and genetic prognostic factors of prostate cancer
    Chakravarti, A
    Zhai, GG
    WORLD JOURNAL OF UROLOGY, 2003, 21 (04) : 265 - 274
  • [12] Molecular markers of prostate cancer
    Bradford, Timothy J.
    Tomlins, Scott A.
    Wang, Xiaoju
    Chinnaiyan, Arul M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (06) : 538 - 551
  • [13] Effectiveness and cost-effectiveness of prognostic markers in prostate cancer
    Calvert, NW
    Morgan, AB
    Catto, JWF
    Hamdy, FC
    Akehurst, RL
    Mouncey, P
    Paisley, S
    BRITISH JOURNAL OF CANCER, 2003, 88 (01) : 31 - 35
  • [14] Effectiveness and cost-effectiveness of prognostic markers in prostate cancer
    N W Calvert
    A B Morgan
    J W F Catto
    F C Hamdy
    R L Akehurst
    P Mouncey
    S Paisley
    British Journal of Cancer, 2003, 88 : 31 - 35
  • [15] Diagnostic and prognostic markers for human prostate cancer
    Gao, X
    Porter, AT
    Grignon, DJ
    Pontes, JE
    Honn, KV
    PROSTATE, 1997, 31 (04) : 264 - 281
  • [16] Prostate cancer: are new prognostic markers on the horizon?
    M Lijovic
    ME Fabiani
    J Bader
    AG Frauman
    Prostate Cancer and Prostatic Diseases, 2000, 3 : 62 - 65
  • [17] Prostate cancer: are new prognostic markers on the horizon?
    Lijovic, M
    Fabiani, ME
    Bader, J
    Frauman, AG
    PROSTATE CANCER AND PROSTATIC DISEASES, 2000, 3 (02) : 62 - 65
  • [18] Molecular markers in the diagnosis of prostate cancer
    van der Poel, H. G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 61 (02) : 104 - 139
  • [19] Molecular markers and mortality in prostate cancer
    Concato, John
    Jain, Dhanpat
    Li, William W.
    Risch, Harvey A.
    Uchio, Edward M.
    Wells, Carolyn K.
    BJU INTERNATIONAL, 2007, 100 (06) : 1259 - 1263
  • [20] An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer
    Broenimann, Stephan
    Pradere, Benjamin
    Karakiewicz, Pierre
    Abufaraj, Mohammad
    Briganti, Alberto
    Shariat, Shahrokh F.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2020, 20 (08) : 841 - 850
12345